Menu Search
Equities

Hofseth Biocare ASA

HBQ:FRA

Hofseth Biocare ASA

Actions
  • Price (EUR)0.0954
  • Today's Change-0.015 / -13.27%
  • Shares traded330.00
  • 1 Year change-59.40%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 08:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hofseth Biocare ASA is a Norway-based biotech company that offers ingredients and finished products for humans and animals. The Company’s business is development, manufacturing, marketing and sale of marine ingredients such as oil, calcium and protein products. Its main products are Salmon protein hydrolysate (ProGo), which is a protein for sports, endurance, and recovery powders; Fresh, all-natural salmon oil (OmeGo) that has a full spectrum of omega fatty acids, including EPA, DHA and DPA, totaling 21 different fatty acids; Calcium bone powder (CalGo) is a natural marine collagenic bone powder and CollaGo is a Collagen Peptide powder optimised to improve the beauty of hair, skin and nails. Hofseth BioCare's headquarters are in Aalesund with branches in Oslo, Chicago, Mumbai, Tokyo and Menlo Park, California.

  • Revenue in NOK (TTM)239.87m
  • Net income in NOK-133.48m
  • Incorporated2009
  • Employees65.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.